BridgeMD
New treatment option for Non-Small Cell Lung Cancer
Official title Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial)
ClinicalTrials.gov ID: NCT07073365
What this study is testing
- What it's testing
- This is a single-arm, open-label, phase II study evaluating the clinical outcomes of local therapy (surgery or radiotherapy) to the primary tumor in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) who have achieved disease control following first-line treatment with the FLAURA2 regimen (osimertinib plus platinum-based chemotherapy). The primary objective is to assess the median progression-free survival (PFS) after local therapy.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 20 and older
You may be able to join if
- \ Participants must meet all of the following criteria to be eligible:
- Age ≥ 20 years at the time of consent.
- Histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC).
- Presence of activating EGFR mutation (exon 19 deletion or L858R).
- Stage IV (metastatic) NSCLC at initial diagnosis.
You likely can't join if
- \> Participants will be excluded if they meet any of the following criteria:
- Radiologic or clinical evidence of progressive disease during first-line osimertinib-chemotherapy.
- Extensive, unresectable metastatic disease not amenable to local therapy.
- Untreated or clinically unstable brain metastases.
- Known contraindications to surgery or radiotherapy.
- Active second malignancy requiring concurrent treatment.
See the full eligibility criteria
- \ Participants must meet all of the following criteria to be eligible:
- Age ≥ 20 years at the time of consent.
- Histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC).
- Presence of activating EGFR mutation (exon 19 deletion or L858R).
- Stage IV (metastatic) NSCLC at initial diagnosis.
- Completion of four cycles of first-line osimertinib plus platinum-based chemotherapy (FLAURA2 regimen).
- Radiologic evidence of disease control (complete response, partial response, or stable disease) after systemic therapy.
- Residual primary lung tumor suitable for local therapy (surgery or radiotherapy), as determined by multidisciplinary evaluation.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Adequate organ function based on institutional laboratory criteria.
- Ability to understand and willingness to provide written informed consent. \<
- \> Participants will be excluded if they meet any of the following criteria:
- Radiologic or clinical evidence of progressive disease during first-line osimertinib-chemotherapy.
- Extensive, unresectable metastatic disease not amenable to local therapy.
- Untreated or clinically unstable brain metastases.
- Known contraindications to surgery or radiotherapy.
- Active second malignancy requiring concurrent treatment.
- Any condition that, in the opinion of the investigator, would interfere with study participation or interpretation of results.
- Pregnancy or breastfeeding at the time of enrollment.
The study team makes the final eligibility decision.
Where it's taking place
- Busan, South Korea
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 20 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Busan, South Korea. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.